| 摘要 |
The monoclonal humanized anti-VEGF (ranibizumab) antibody fragment has been used in doses of from about 0.3 mg to about 0.05 mg/0.5 mL (300 Ág to about 500 Ág/0.05 mL) for treating the diabetic macular edema due to a complete blocking of the intravitreous VEGF; however, the VEGF is a molecule necessary for the cellular health of the retina. Proposed is a method for obtaining micro-doses of the monoclonal humanized anti-VEGF antibody fragment at doses of from about 30 Ág/mL to about 250 Ág/mL for the treatment of the diabetic macular edema which offers a clinical improvement without the potential side effects of usual doses.
|
